23014 results for "ega"

in 27.97 milliseconds.

• Expression signatures of NGLY1 deficiency

  Study EGAS00001005573

• Mitochondrial DNA sequencing

  Study EGAS00001005540

• Patient-derived organoids_Vumc

  Study EGAS00001005947

• Genomic History of Siberia

  Study EGAS00001006089

• WGS of PMBCL

  Study EGAS00001006452

• HLF COPD DNA Methylomics

  Study EGAS00001006603

• GLASS-NL DNA-Methylation

  Study EGAS00001007546

• Inform-Lynch-Syndrome-Access

  Dac EGAC00001003315

• Rehnitz working group Heidelberg

  Dac EGAC50000000414

• EMBARCAM BC360 PROJECT Data Access Committee

  Dac EGAC00001003517

• CROATIA-Korcula Study

  Study EGAS00001008043

• DAC for EGAS00001007531

  Dac EGAC00001003437

• University Medical Center Groningen MMBI

  Dac EGAC50000000614

• HCA | Organoid - Colon

  Dac EGAC00001003532

• trained immunity data reception

  Dac EGAC00001003518

• Personalis, Inc. Data Access Committee

  Dac EGAC50000000325

• CCIT-DK DAC

  Dac EGAC50000000191

• Heritable pulmonary arterial hypertension

  Dac EGAC50000000746

• CCI's open access data requests

  Dac EGAC00001001863

• BIOCLOCK Data Access Committee

  Dac EGAC00001003573

• UCL Centre for Longitudinal Studies

  Dac EGAC00001003495

• DAC for v9 panel assay

  Dac EGAC00001003580

• WES in plasma cell neoplasms

  Dac EGAC50000000813

• LUMC Department Immunology, Staal Group

  Dac EGAC50000000952

• UCSF CASCADE Data Access Committee

  Dac EGAC00001003185

• Exome_sequencing_of_Non_syndromic_Congenital_Heart_Defects

  tbc

  Study EGAS00001001734

• Histone modifications of cfDNA

  Study EGAS00001006503

• Clinical validity of post-surgery circulating tumor DNA (ctDNA) in stage III colon cancer patients treated with adjuvant chemotherapy: the PROVENC3 study

  The PROVENC3 study aimed to determine the clinical validity of post-surgery ctDNA testing in patients with stage III colon cancer treated with adjuvant chemotherapy (ACT). Blood was collected pre-surgery, post-surgery and post-adjuvant chemotherapy. Tumor-informed plasma ctDNA detection was performed through integrated whole genome sequencing (WGS) analyses of formalin-fixed paraffin-embedded tumor tissue DNA (80x), white blood cell germline DNA (40x) and plasma cell-free DNA (30x). These raw WGS data for 209 patients are shared in .cram format in this EGA submission. For 196/209 of these patients there is overlapping FFPE tumor RNA sequencing data available, shared in .fastq format in this EGA submission.

  Study EGAS50000000804

• MALT1 in MCL data access commitee

  Dac EGAC00001002989

• DAC for the study EGAS00001001738

  Dac EGAC00001000450

• ALI-RSV study Data Access Commitee

  Dac EGAC00001003371

• MX Biobank Data Access Committee

  Dac EGAC00001002413

• VIB-UZL Data Access Committee

  Dac EGAC00001003377

• WEHI- Labat - human lung cell data

  Dac EGAC00001000651

• VIB-UZL Data Access Committee

  Dac EGAC00001002806

• Data access commitee to DAISY study

  Dac EGAC00001003031

• Human Origins African Data Access Commitee

  Dac EGAC00001003070

• HNO Team Data Access Committee

  Dac EGAC00001002801

• LYMPHGEN Data Access Commitee

  Dac EGAC00001002875

• LifeLines-NEXT data access commitee

  Dac EGAC00001003388

• DAC for sputum fungal microbiome data

  Dac EGAC00001003006

• DAC for Oncogenomics QIMR Berghofer

  Dac EGAC00001001088

• DAC Whole-Exome Sequencing data Algeria

  Dac EGAC00001003231

• DAC Genome-wide array data Algeria

  Dac EGAC00001003230

• Institut Pasteur CoSImmGEn-F cohort

  Dac EGAC00001003235